Discovery of a Novel Stilbene Derivative as a Microtubule Targeting Agent Capable of Inducing Cell Ferroptosis

Area of Science:

• Medicinal Chemistry
• Cancer Biology
• Drug Discovery

Background:

• Microtubule targeting agents (MTAs) are established cancer chemotherapies.
• Acquired or intrinsic resistance to apoptosis limits MTA efficacy.
• Ferroptosis presents a promising alternative cell death pathway for therapy-resistant cancers.

Purpose of the Study:

• To synthesize novel MTAs based on previously identified compounds.
• To investigate structure-activity relationships and identify potent anti-cancer agents.
• To explore alternative cell death mechanisms for overcoming drug resistance.

Main Methods:

• Synthesis of a series of microtubule targeting agents.
• Extensive molecular dynamics studies for structure-activity relationship analysis.
• In vitro and in vivo evaluation of compound efficacy and mechanism of action.

Main Results:

• Compound 33, a diphenylethene derivative, showed potent in vitro activity (10-50 nM IC50) against six cancer cell lines.
• Compound 33 demonstrated significant in vivo tumor growth inhibition (78.6%).
• Compound 33 induced cancer cell death primarily through ferroptosis, not apoptosis.

Conclusions:

• Compound 33 is a potent anti-cancer agent with a novel mechanism of action.
• Targeting ferroptosis offers a viable strategy to overcome apoptosis-related drug resistance in cancer.
• This study provides a new avenue for developing effective cancer therapeutics.